Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Considerations in the Selection of PARP Inhibitors for Patients With Ovarian Cancer

Choosing among PARP inhibitors can be challenging. Listen to global expert discuss their considerations for picking among PARP inhibitors as frontline maintenance for ovarian cancer.
Nicoletta Colombo, MD
Thomas J. Herzog, MD
Ignace Vergote, MD, PhD
Released: May 21, 2021 Expiration: No longer available for credit

Related Content

7-year follow-up from phase III SOLO-1 trial of maintenance olaparib vs placebo in newly diagnosed advanced ovarian cancer, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 15, 2022

Interactive online tool with expert management recommendations for selecting therapy for women with advanced endometrial cancer, from Clinical Care Options (CCO)

Maria Bell, MD, MPH, MBA Hye Sook Chon, MD Linda R. Duska, MD, MPH Ritu Salani, MD, MBA Shannon N. Westin, MD, MPH Released: September 13, 2022

Final OS data for PAOLA-1 phase III trial of maintenance olaparib plus bevacizumab vs placebo plus bevacizumab in newly diagnosed ovarian cancer, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Released: September 13, 2022

Experts highlight key studies being reported at the upcoming 2022 ESMO Congress in this commentary from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Released: September 8, 2022

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This educational activity is supported by an educational grant from
GlaxoSmithKline

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings